...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Laryngoscope: A Medical Journal for Clinical and Research Contributions in Otolaryngology, Head and Neck Medicine and Surgery, Facial Plastic and Reconstructive Surgery .. >Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: A Systematic Review
【24h】

Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: A Systematic Review

机译：皮下免疫治疗对过敏性鼻咽炎和哮喘的有效性：系统评价

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives/Hypothesis To systematically review the effectiveness and safety of subcutaneous immunotherapy (SCIT) for treatment of allergic rhinoconjunctivitis and asthma, using formulations currently approved in the United States. Study Design We searched the following databases up to May 21, 2012: MEDLINE, Embase, LILACS, and the Cochrane Central Register of Controlled Trials. Methods We included randomized controlled trials published in English comparing SCIT to placebo, pharmacotherapy, or other SCIT regimens that reported clinical outcomes of interest. Studies of adults or mixed age populations were included. Studies were excluded if the diagnosis of allergy and/or asthma was not confirmed with objective testing. Paired reviewers selected articles for inclusion and extracted data. We assessed the risk of bias for each study and graded the strength of evidence for each outcome as high, moderate, or low. Results Sixty-one studies met our inclusion criteria. Majority of the studies (66%) evaluated single-allergen immunotherapy regimens. The literature provides high-grade evidence that SCIT reduces asthma symptoms, asthma medication usage, rhinitis/rhinoconjunctivitis symptoms, conjunctivitis symptoms, and rhinitis/rhinoconjunctivitis disease-specific quality of life in comparison to placebo or usual care. There is moderate evidence that SCIT decreases rhinitis/rhinoconjunctivitis medication usage. Respiratory reactions were the most common systemic reaction. There were few reports of anaphylaxis; no deaths were reported. Conclusions Generally moderate to strong evidence supports the effectiveness of SCIT for treatment of allergic rhinitis and asthma, particularly with single-allergen immunotherapy regimens. Adverse reactions to SCIT are common, but no deaths were reported in the included studies.
机译：目的/假设系统地审查皮下免疫疗法（SCIT）治疗过敏性鼻咽炎和哮喘的疗效和安全性，使用当前在美国批准的制剂进行治疗。研究设计我们在2012年5月21日的下列数据库中搜索了以下数据库：Medline，Embase，Lilacs和受控试验的Cochrane中央登记。方法包括在英语中公布的随机对照试验比较放置到安慰剂，药物治疗或其他报告临床结果的水肺方案。包括成人或混合年龄种群的研究。如果没有通过客观测试证实过敏和/或哮喘的诊断，则排除研究。配对的审阅者选择包含和提取数据的文章。我们评估了每项研究的偏见的风险，并将每个结果的证据强度分级为高，中等或低。结果六十一项研究达到了纳入标准。大多数研究（66％）评估了单体过敏原免疫治疗方案。该文献提供了高档证据，即滑雪可降低哮喘症状，哮喘药物用途，鼻炎/鼻咽炎症状，结膜炎症状和鼻炎/鼻炎/鼻咽炎与安慰剂或通常的护理相比，具体的生活质量。粪便有适度的证据，降低鼻炎/鼻咽炎药物用途。呼吸反应是最常见的全身反应。关于过敏反应的报道很少;没有报告死亡。结论一般来适中的证据支持适用于治疗过敏性鼻炎和哮喘的粪便的有效性，特别是单过敏原免疫治疗方案。对粪便的不良反应是常见的，但在内的研究中没有报告死亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号